![](https://cdn.sanity.io/images/0vv8moc6/pharmexec/4dc8686350a41488bbe672569def209c8f9014af-1280x720.png?fit=crop&auto=format)
The Transformative Potential of AI and Machine Learning in Biomedical Research and Healthcare
admin December 23, 2023 ArticleIn a recent article published by Oxford Academic, authors discussed a number of ways that artificial intelligence (AI) and machine learning (ML) could transform biomedical research and healthcare. This includes enhancing operational efficiency, reducing costs, improving diagnostics, identifying therapeutic targets, and enabling personalized treatment. Despite these opportunities, challenges, such as responsible and ethical implementation, workforce […]
![](https://www.pharmexec.com/Logos-02-color.png)
Published on: December 21, 2023 Explore the implementation of enterprise laboratory software and the start of a digital transformation in your lab with an industry expert who discusses maximizing returns on investment, upholding data integrity while managing cost containment, and adopting digital best practices. This podcast addresses critical topics such as cybersecurity, regulatory compliance and fiscal […]
![](https://cdn.sanity.io/images/0vv8moc6/pharmexec/b6cd19db7a10bd68fb3dd801292f26fe9b661898-1280x720.png?fit=crop&auto=format)
79% of Respondents Admit to Neglecting Health Needs During the Holiday Season
admin December 22, 2023 ArticleAmerican Heart Association survey suggests holiday stress has a major impact on health habits. A recent survey released by the American Heart Association revealed that 79% of respondents tend to neglect their health needs during the holidays, focusing instead on creating special moments for others. Additionally, 51% of Americans state that they take weeks to […]
![](https://cdn.sanity.io/images/0vv8moc6/pharmexec/80bc71c40169b1ace20e7b67d9e6af31ef7876c3-1920x1080.jpg?fit=crop&auto=format)
Q&A With Christoph Bug, Vice President of Global Medical at Veeva
admin December 21, 2023 ArticleData will continue to grow in importance in 2024. Many of the biggest stories in 2023 were related to technological advancements in the life sciences industry. These advancements have increased the importance of having high-quality data. Christoph Bug, vice president of global medical at Veeva, spoke with Pharmaceutical Executive about the trends he sees coming […]
![](https://cdn.sanity.io/images/0vv8moc6/pharmexec/32435267bfd70b36fa03881a9de2530fe188ef22-4184x3173.jpg?fit=crop&auto=format)
FDA Grants Priority Review to Genentech’s sBLA for Xolair to Treat Food Allergies
admin December 21, 2023 ArticleIf approved by the FDA, Xolair would be the first drug indicated to lower allergic reactions to multiple foods after an accidental exposure, including peanut, milk, and egg allergies. The FDA has granted Priority Review to Genentech’s supplemental Biologics License Application (sBLA) for Xolair (omalizumab) for the treatment of allergic reactions, such as anaphylaxis, that may result […]
![](https://cdn.sanity.io/images/0vv8moc6/pharmexec/8b098d7cd4ac4944be8ab09a99873bb95e2efc86-1280x720.png?fit=crop&auto=format)
Study Finds Association Between Neighborhood-Level Socioeconomic Status, Medication Nonadherence Among Heart Failure Patients
admin December 20, 2023 ArticleJAMA study aims to discover whether ignoring medical advice relates to financial status among patients with heart failure. Recently published research points to a need for greater outreach efforts to improve medication uptake among underserved patient populations. In a JAMA Network study published last week, the authors set out to discover whether medication nonadherence amongst […]
![](https://cdn.sanity.io/images/0vv8moc6/pharmexec/05007d0f0915812ee7d4e7c9f3c2c6ce29775c90-7306x4110.jpg?fit=crop&auto=format)
Merck’s 21-Valent Pneumococcal Conjugate Vaccine Granted FDA Priority Review
admin December 19, 2023 ArticleMerck’s Biologics License Application for V116, a novel 21-valent pneumococcal conjugate vaccine has been given a Prescription Drug User Fee Act (PDUFA) date of June 17, 2024. The FDA has granted priority review to Merck’s Biologics License Application (BLA) for V116, a novel 21-valent pneumococcal conjugate vaccine developed as a single dose for the prevention […]
![](https://cdn.sanity.io/images/0vv8moc6/pharmexec/448e0996899f139daf2bf50ab445f36e9677884b-9271x4124.jpg?fit=crop&auto=format)
In the coming year, efficiency and automation will take center stage to maximize constrained resources but balancing sensible financial management with strategic investments will be vital. The breakneck pace of digital transformation spurred by COVID-19 continued to reshape the life sciences landscape in 2023. Rather than a single watershed moment, this year marked an inflection […]
![](https://cdn.sanity.io/images/0vv8moc6/pharmexec/4062c91586e780f15940fa1753d214485fa838e4-6000x4000.jpg?fit=crop&auto=format)
FDA Approves Padcev/Keytruda Combo for Locally Advanced, Metastatic Urothelial Cancer
admin December 18, 2023 ArticleIn clinical trials, Padcev (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab) produced a statistically significant improvement in survival compared to platinum-based chemotherapy alone in patients with locally advanced or metastatic urothelial cancer. The FDA has approved Padcev (enfortumab vedotin-ejfv; Astellas Pharma and Seagen [now owned by Pfizer]) plus Keytruda (pembrolizumab; Merck) for patients with locally advanced or […]